3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Glioblastoma
154
Brain Neoplasms
73
Glioma
69
Central Nervous System Neoplasms
50
Gliosarcoma
46
Astrocytoma
37
Melanoma
36
Oligodendroglioma
29
Neuroblastoma
17
Neoplasm Metastasis
14
Carcinoma, Non-Small-Cell Lung
12
Lung Neoplasms
11
Sarcoma, Ewing
10
Sarcoma
10
Neoplasms
10
Medulloblastoma
10
Recurrence
9
Neuroendocrine Tumors
9
Lymphoma
8
Ependymoma
8
Breast Neoplasms
8
Small Cell Lung Carcinoma
7
Rhabdomyosarcoma
7
Diffuse Intrinsic Pontine Glioma
7
Colorectal Neoplasms
7
Carcinoma, Neuroendocrine
6
Adenoma, Islet Cell
6
Uveal Melanoma
5
Spinal Cord Neoplasms
5
Pheochromocytoma
5
Interventions
lutetium Lu 177 dotatate
2
copper dotatate CU-64
2
Etoposide
2
zimberelimab
1
folfirinox
1
famitinib
1
cabozantinib
1
abemaciclib
1
Temozolomide
1
Nivolumab
1
Lutetium-177
1
Lutetium
1
Irinotecan
1
Granulocyte Colony-Stimulating Factor
1
Fluorodeoxyglucose F18
1
Filgrastim
1
Cytokines
1
Cryotherapy
1
Copper
1
Cisplatin
1
Carboplatin
1
Acupuncture Therapy
1
Acupressure
1
64Cu-DOTATATE
1
177Lu-octreotide, DOTA(0)-Tyr(3)-
1
11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Gastro-enteropancreatic neuroendocrine tumor
×
Temozolomide
×
Clear all
NCT04893785
2024-06-18
CABOTEM
National Cancer Institute, Naples
Phase 2
Recruiting
35 enrolled